


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	DEFOROLIMUS
PRONUNCIATION	def oh roe' li mus
THERAPEUTIC CLAIM	Antineoplastic

CHEMICAL NAMES

- Rapamycin, 42-(dimethylphosphinate)
- (1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*,23*S*,24*E*,26*E*,28*E*,30*S*,32*S*,35*R*)-12-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-[(dimethylphosphinoyl)oxy]-3-methoxycyclohexyl]-1-methylethyl]-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxo-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-tetraene-2,2,3,3,10,20-pentone

STRUCTURAL FORMULA



RESCINDED

MOLECULAR FORMULA	C ₅₃ H ₈₄ NO ₁₄ P
MOLECULAR WEIGHT	990.2
CODE	AP23573
TRADEMARK	None as yet
MANUFACTURER	Ariad Pharmaceuticals
<u>CAS</u> REGISTRY NUMBER	572924-54-0

NOTES: 1) The name *deforolimus* is hereby rescinded; please see adoption statement for *ridaforolimus*.